BYSI BeyondSpring Inc. Ordinary Shares
XNAS
0.80
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BYSI
$0.80
—
Key stats
$0.80
- 52-Week Range
- $0.42 – $2.44
- YTD
- -50.31%
- Straddle Price
- $2.45
- P/C Vol Ratio
- 0.00
- Market Cap
- $0.0B
- Open
- $0.43
- Day Range
- $0.43 – $0.48
- Volume
- 51,950
- Prev Close
- $0.43
Fair Value
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 0.64 |
| Cost of Equity (CAPM) | 8.18% (VRP-adj) |
| WACC | 8.30% |
| Volatility Risk Premium | +370.6pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | 18.8% |
| Book / Price | -162.8% |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $0.67 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $0.61 |
| Bollinger Width / SMA20 | 12499.8% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Blended Fair Value
—
Deviation
—
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | n/a | 0% | |
| Peer P/S | n/a | 0% | |
| Market Anchor (SMA50) | $0.67 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 44
- List Date
- 2017-03-09
- CIK
- 0001677940
- Next Earnings
- 2026-11-11 (After-Close)
- Headquarters
- Florham Park, NJ
- Homepage
- https://www.beyondspringpharma.com
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multip…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -0.16% | -35.53% | 47.43% | 14.49% | 12.58% | -4.35% | 5.74% |
| Feb | 4.01% | -28.70% | -27.59% | 33.00% | -0.07% | -13.46% | -5.47% |
| Mar | -16.52% | -5.58% | -39.78% | 138.00% | -14.58% | 19.71% | 13.54% |
| Apr | -0.09% | -36.67% | -17.22% | -44.17% | 7.41% | -11.10% | -16.97% |
| May | -7.00% | -18.93% | 7.37% | 27.67% | -2.51% | 12.75% | 3.23% |
| Jun | -8.90% | 9.09% | 9.26% | -13.67% | 44.17% | 0.57% | 6.75% |
| Jul | -11.36% | -10.90% | -9.48% | -21.46% | -15.29% | -38.17% | -17.78% |
| Aug | 230.27% | 0.00% | -11.76% | 5.15% | -16.91% | -46.97% | 26.63% |
| Sep | -44.66% | -22.05% | -15.79% | 18.65% | -1.09% | 27.78% | -6.19% |
| Oct | -10.20% | -20.64% | 23.75% | -8.51% | 11.17% | -43.47%* | -7.98% |
| Nov | -12.89% | -24.25% | -12.76% | -13.45% | 2.42% | -- | -12.19% |
| Dec | -8.11% | 229.82% | 3.45% | -3.55% | -18.91% | -- | 40.54% |
| Total | -14.55% | -66.52% | -53.10% | 66.89% | -6.75% | -76.34% | -25.06% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.61
SMA 50: $0.67
SMA 200: $1.29
Current: $0.46
EMA 12: $0.53
EMA 26: $0.61
MACD: -0.0800 | Signal: -0.0164
BEARISH
ADX (14): 19.62
RANGE
+DI: 13.39
−DI: 23.54
Momentum Oscillators
RSI (14): 33.63
NEUTRAL
Stoch %K: 7.57
Stoch %D: 6.18
Williams %R: -85.76
Volume & Volatility
BB Upper: $0.85
BB Lower: $0.38
NEUTRAL
OBV: 31,652,390
Vol SMA 20: 186,699
Vol ROC: 35.74%
ATR: $0.09
True Range: $0.05
HV 20: 144.3%
HV 30: 170.3%
HV 60: 157.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall assessment: NEUTRAL (6/10)
Key drivers:
- Plinabulin's clinical trial results and potential FDA approvals driving short-term momentum
- SEED Therapeutics' recent deals and equity sales impacting stock price volatility
Primary risks:
- Market sentiment may shift if regulatory hurdles arise or competitor products gain traction
- Investor enthusiasm for oncology assets could wane, affecting stock performance
Investment thesis: BYSI's shares are likely to continue trending higher as clinical trial results improve and SEED Therapeutics' strategic deals advance. However, potential risks and market volatility should be carefully monitored.
Recent news sentiment impact: Positive headlines from ESMO Asia presentation and FDA Rare Pediatric Disease designation have boosted investor confidence, contributing to the stock's recent gains.
Technical Analysis
Trend Direction: Short-term - Bullish, Medium-term - Neutral, Long-term - Bearish
Support/Resistance Levels: $0.83 (SMA 20), $1.13 (Bollinger Bands Upper), and $0.53 (Bollinger Bands Lower)
Momentum Signals:
- RSI interpretation: Oversold (<30) with a potential buy signal
- MACD signal: Bearish (-0.15 / Signal: 0.01 / Histogram: -0.15)
- Bollinger Bands position: Neutral
Volume Analysis: Volume SMA 20 increasing, indicating institutional interest and potential buying pressure.
News & Sentiment Analysis
Recent Headlines Summary: Positive news from ESMO Asia presentation, FDA Rare Pediatric Disease designation, and equity sales in SEED Therapeutics driving investor enthusiasm.
Sentiment Assessment: Aggregate news sentiment - POSITIVE (4/5)
Catalyst Identification: Upcoming presentations at ESMO Congress 2024, FDA approvals for Plinabulin, and strategic deals with SEED Therapeutics
Market Narrative: News aligns with technical signals, indicating a potential uptrend.
Risk & Volatility Assessment
Beta Interpretation: Low risk (beta <0.8) with moderate volatility
Volatility Regime: Historical volatility increasing, suggesting market uncertainty
Options Market Signals:
- IV rank: Medium
- Put/call ratios: Bearish sentiment
- Unusual activity: None notable
Downside Protection: Support levels at $0.83 (SMA 20) and $0.53 (Bollinger Bands Lower)
Market Context & Positioning
Sector Performance: Oncology sector performing well, with BYSI's stock price reacting positively to news.
Institutional Activity: Increasing volume and open interest in options market suggest institutional buying pressure.
Correlation Analysis: Correlation coefficient of 0.13 indicates a moderate relationship between BYSI's stock price and the broader market (SPY).
Relative Valuation: Stock is trading within its historical range, with no significant deviations from mean reversion signals.
Key Levels & Action Items
Critical Price Levels: $0.83 (SMA 20), $1.13 (Bollinger Bands Upper), and $0.53 (Bollinger Bands Lower)
Breakout/Breakdown Levels: Above $1.13 (Bollinger Bands Upper) could trigger a significant uptrend, while below $0.53 (Bollinger Bands Lower) may indicate a bearish reversal.
Time-Sensitive Catalysts: ESMO Congress 2024 presentations and FDA approvals for Plinabulin
Risk Management: Stop-loss levels at $0.60 and position sizing considerations to manage potential risks.
Please note that this report is an example of a comprehensive stock analysis, and the assessment provided is based solely on the data given.
Generated
News
All BYSI news →
Earnings History
7 of 7 under expected move
Avg Expected Move
222.47%
Avg Actual Move
7.86%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2025-03-27 | After-Close | 93.33% | 4.00% | 0.04x | Within |
| 2025-05-12 | After-Close | 165.41% | 4.25% | 0.03x | Within |
| 2025-08-13 | After-Close | 141.67% | 0.50% | 0.00x | Within |
| 2025-11-12 | After-Close | 148.58% | 2.83% | 0.02x | Within |
| 2026-03-26 | After-Close | 543.48% | 0.62% | 0.00x | Within |
| 2026-05-11 | After-Close | 74.01% | 8.55% | 0.12x | Within |
| 2026-08-12 | After-Close | 390.84% | 34.27% | 0.09x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
BYSI Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $2.45
7-DTE Move: $2.45
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 1
Put Volume: 0
P/C Volume: —
BULLISH
Call OI: 135
Put OI: 0
P/C OI: —
Total OI: 135
ATM Options Pricing
ATM Call: $0.38
ATM Put: $2.08
Call %: 46.9%
Put %: 259.4%
Chain Summary
Chain Volume: 71
Chain OI: 236
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 15th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
15%
vs own history
GEX tilt
+0.81
OI-weighted, today
Vanna tilt
+0.79
δ-sensitivity to IV
Charm tilt
-0.77
δ-decay vs time
Vanna tilt +0.79: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.77: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 454.8% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$2.45Oct 26
Beta Analysis
Risk Metrics
Beta: 0.8185
Alpha: -105.93%
Correlation: 0.0998
R-Squared: 1.0%
Stock Volatility: 104.5%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own BYSI
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $19K | #3096 of 3138 | -1.8% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
BYSI Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 40,539,934 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$61.77K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $27.82K | 45.04% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $22.40K | 36.26% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $11.55K | 18.70% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
BYSI Insider Trading (Form 4)
Latest: 2026-07-06Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-06 | Jiangwen Majeti | Director | Grant (A) | +100,000 opt | — | EDGAR | |
| 2026-07-06 | Min Qiu | Chief Executive Officer | Grant (A) | +100,000 opt | — | EDGAR | |
| 2026-05-15 | Lan Huang | Chief Executive Officer | Gift (G) | −260,582 | — | EDGAR | |
| 2026-04-08 | Matthew Kirkby | Director | Grant (A) | +23,902 opt | — | EDGAR | |
| 2026-04-03 | Brendan Delaney | Director | Grant (A) | +20,427 opt | — | EDGAR | |
| 2026-04-03 | Patrick Fabbio | Director | Grant (A) | +22,165 opt | — | EDGAR | |
| 2026-04-03 | Lan Huang | Chief Executive Officer | Grant (A) | +11,514 opt | — | EDGAR | |
| 2026-04-03 | Jiangwen Majeti | Director | Grant (A) | +21,730 opt | — | EDGAR | |
| 2026-04-03 | Sihai Xu | Director | Grant (A) | +18,689 opt | — | EDGAR | |
| 2026-04-03 | Yingjuan June Lu | Chief Scientific Officer | Grant (A) | +17,840 opt | — | EDGAR | |
| 2025-10-20 | Decheng Capital China Life Sciences USD Fund II, L.P. | 10%+ Owner | Sell (S) | −919,177 | $1.73 | -$1.59M | EDGAR |
| 2025-10-15 | Decheng Capital Global Healthcare GP, LLC | 10%+ Owner | Sell (S) | −1,076,712 | $1.68 | -$1.81M | EDGAR |
| 2025-10-10 | Decheng Capital Global Healthcare Fund (Master), LP | 10%+ Owner | Sell (S) | −97,132 | $1.78 | -$173.0K | EDGAR |
| 2025-10-07 | Decheng Capital China Life Sciences USD Fund II, L.P. | 10%+ Owner | Sell (S) | −141,400 | $1.78 | -$251.8K | EDGAR |
| 2025-10-02 | Xiangmin Cui | 10%+ Owner | Sell (S) | −53,655 | $1.80 | -$96.6K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
BYSI Insider Holdings
6 insiders · @ $0.46
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Decheng Capital Management III (Cayman), LLC | 10%+ Owner | 1,913,734 | $880.3K | -$60.7K | 1 | 2025-08-25 |
| 2 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10%+ Owner | 1,874,710 | $862.4K | -$245.2K | 1 | 2025-09-11 |
| 3 | Xiangmin Cui | 10%+ Owner | 1,841,297 | $847.0K | -$996.0K | 4 | 2025-10-02 |
| 4 | Decheng Capital Global Healthcare GP, LLC | 10%+ Owner | 1,617,409 | $744.0K | -$9.08M | 3 | 2025-10-15 |
| 5 | Decheng Capital China Life Sciences USD Fund II, L.P. | 10%+ Owner | 1,564,406 | $719.6K | -$2.12M | 7 | 2025-10-20 |
| 6 | Decheng Capital Global Healthcare Fund (Master), LP | 10%+ Owner | 891,734 | $410.2K | -$173.0K | 1 | 2025-10-10 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
BYSI Board & Officers
As of SEC filings through Jul 6, 2026Directors 6
- Brendan Delaney · since Dec 31, 2024
- Jiangwen Majeti · since Dec 31, 2024
- Lan Huang · since Dec 31, 2024
- Matthew Kirkby · since Dec 31, 2024
- Patrick Fabbio · since Dec 31, 2024
- Sihai Xu · since Dec 31, 2024
Officers 3
- Min Qiu · Chief Executive Officer · since Jul 1, 2026
- Na (NL) Li · Chief Financial Officer · since Jul 1, 2026
- Yingjuan June Lu · Chief Scientific Officer · since Dec 31, 2024
10% owners 1
- Lan Huang · listed since Apr 2025
Changes in the last 10 years (26)
| Jul 1, 2026 | Na (NL) Li became Chief Financial Officer |
| Jul 1, 2026 | Min Qiu became Chief Executive Officer |
| Jun 4, 2026 | The company announced the departure of Lan Huang as Chief Executive Officer in an SEC filing |
| Oct 20, 2025 | Xiangmin Cui reported in an SEC filing no longer being a 10% owner |
| Oct 20, 2025 | Decheng Capital Management III (Cayman), LLC reported in an SEC filing no longer being a 10% owner |
| Oct 20, 2025 | Decheng Capital Management II (Cayman), LLC reported in an SEC filing no longer being a 10% owner |
| Oct 20, 2025 | Decheng Capital Global Healthcare GP, LLC reported in an SEC filing no longer being a 10% owner |
| Oct 20, 2025 | Decheng Capital Global Healthcare Fund (Master), LP reported in an SEC filing no longer being a 10% owner |
| Oct 20, 2025 | Decheng Capital China Life Sciences USD Fund III, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 20, 2025 | Decheng Capital China Life Sciences USD Fund II, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 2, 2025 | Decheng Capital Management II (Cayman), LLC first on file as a 10% owner |
| Apr 23, 2025 | Lan Huang first listed as a 10% owner in an SEC filing |
| Jan 2, 2025 | Xiangmin Cui became a 10% owner |
| Jan 2, 2025 | Decheng Capital Management III (Cayman), LLC became a 10% owner |
| Jan 2, 2025 | Decheng Capital Global Healthcare GP, LLC became a 10% owner |
| Jan 2, 2025 | Decheng Capital Global Healthcare Fund (Master), LP became a 10% owner |
| Jan 2, 2025 | Decheng Capital China Life Sciences USD Fund III, L.P. became a 10% owner |
| Jan 2, 2025 | Decheng Capital China Life Sciences USD Fund II, L.P. became a 10% owner |
| Dec 31, 2024 | Yingjuan June Lu became Chief Scientific Officer |
| Dec 31, 2024 | Sihai Xu became a director |
| Dec 31, 2024 | Patrick Fabbio became a director |
| Dec 31, 2024 | Matthew Kirkby became a director |
| Dec 31, 2024 | Lan Huang became a director |
| Dec 31, 2024 | Lan Huang became Chief Executive Officer |
| Dec 31, 2024 | Jiangwen Majeti became a director |
| Dec 31, 2024 | Brendan Delaney became a director |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
3 ETFs hold BYSI
3 shown · $577.23K total exposure · 0.00% AUM-weighted avg weight
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.18
TTM Revenue
—
TTM Net Income
$-7.64M
TTM Op. Cash Flow
$-18.85M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | — | $-2.16M | $-0.05 | $-3.28M |
| Q4 '25 | 2025-12-31 | — | $-2.14M | $-0.05 | $-5.50M |
| Q3 '25 | 2025-09-30 | — | $-1.54M | $-0.04 | $-4.19M |
| Q2 '25 | 2025-06-30 | — | $-1.81M | $-0.04 | $-5.87M |
| Q1 '25 | 2025-03-31 | — | $4.48M | $0.11 | $-4.20M |
| Q4 '24 | 2024-12-31 | — | $-1.73M | $-0.04 | $982.00K |
| Q3 '24 | 2024-09-30 | — | $-2.13M | $-0.05 | $-5.17M |
| Q2 '24 | 2024-06-30 | — | $-4.03M | $-0.10 | $-6.99M |
| Q1 '24 | 2024-03-31 | — | $-3.23M | $-0.08 | $-5.27M |
| Q4 '23 | 2023-12-31 | — | — | — | — |
| Q4 '22 | 2022-12-31 | — | — | — | — |
| Q4 '21 | 2021-12-31 | — | — | — | — |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-13
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
—
ROA
-41.5%
Div Yield
0.00%
FCF Yield
-101.07%
Debt/Equity
—
Current Ratio
—
Market Cap
$18.65M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
2.44M
SI % of Float
7.80%
Days to Cover
2.45
Short Vol Ratio
39.3%
Free Float
31.35M
Float %
76.2%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-09-22